SGLT2 inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. The peer-reviewed publication discussed in this webcast was independently developed by the Improving Diabetes Steering Committee and the Committee remains independent from Napp in the delivery of their commentary on this peer-reviewed publication within this promotional webcast. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.

SGLT2 inhibitors:

Slowing of chronic kidney disease progression in

type 2 diabetes

Join us for our upcoming promotional webcast taking place on the 28 January 2021 at 13:00 and 19:00

SGLT2 inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes

We are very pleased to announce that the Napp sponsored webcast ‘SGLT2 Inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes’ is now open for registration.

Diabetic Kidney Disease (DKD) is of increasing importance to clinicians involved in the care and management of people with type 2 diabetes, and early detection is essential to improve outcomes.

This webcast has been developed to examine the latest guidance discussed in a recently published consensus statement.1

Attending will provide insights into:

  • How regular renal reviews and monitoring of ACR and eGFR are essential in slowing progression to end stage kidney disease
  • The renoprotective effects of SGLT2 inhibitors drawing on evidence from recent studies such as CREDENCE
  • The international guidelines on the use of SGLT2 inhibitors and implications for clinical practice

 

This 45-minute webcast will be broadcast on 28 January 2021 at both 13.00 and 19.00. Each broadcast will be followed by a 15-minute live Q&A session where you can ask your questions to the expert speakers.

Reference 1. Wheeler DC et al. Diabetes Ther 2020;11:1–18
ACR=albumin creatinine ratio; eGFR=estimated glomerular filtration rate; SGLT2=sodium-glucose co-transporter-2

Join us for our upcoming promotional
webcast taking place on the

28 January 2021
13:00 and 19:00

Your speakers

Dr Sarah Davies (Chair)

GP Partner Woodlands Medical Centre, Cardiff

Sarah Davies is a GP in Cardiff with a special interest in diabetes. She qualified at the University of Wales College of Medicine in 2003 and initially trained as a physician, before making the move into general practice and never looked back! She has continued her interest in diabetes and presents regularly on the subject to colleagues at local and national meetings. She is passionate about general practice, particularly great quality diabetes care in the primary care setting. Dr Davies is the Clinical Director for Diabetes in primary care for Cardiff and Vale UHB.  She is a Diabetes UK Clinical Champion, Primary Care Diabetes Society committee member and a presenter for NB Medical Hot Topics, leading their diabetes course.

Dr Kevin Fernando

GP Partner, North Berwick Health Centre; GPwSI in Diabetes & Medical Education

Kevin Fernando is a part-time GP Partner working at the coalface in North Berwick Health Centre, near Edinburgh. He is a Primary Care Diabetes Society committee member and also Scottish lead. Other roles include RCGP Clinical Advisor for diabetes and multimorbidity and also writer and presenter for the NB Medical Education Hot Topics GP Update courses. He is an alumnus of the Diabetes UK Clinical Champion programme.
Dr Fernando graduated from Edinburgh University in 2000 and holds both MRCGP and MRCP (UK) qualifications and has completed a Master’s degree in diabetes which he passed with distinction.
He has been elected to Fellowship of both the Royal College of General Practitioners and the Royal College of Physicians of Edinburgh for his work in diabetes and medical education. He is also a Member of the Academy of Medical Educators.

Professor John Wilding

Professor of Medicine, University of Liverpool, Liverpool

John Wilding leads Clinical Research into Obesity, Diabetes and Endocrinology at the University of Liverpool. He graduated from Southampton University in 1985, where he continued his clinical training until moving to the Royal Postgraduate Medical School at Hammersmith Hospital, London where he undertook specialist training in Diabetes and Endocrinology, and three years laboratory-based research into the neurobiology of obesity and diabetes. He has been clinical academic at the University of Liverpool since 1996 and was appointed Professor of Medicine in 2005. He leads specialist services for severe obesity at University Hospital Aintree – designated a Centre for Obesity Management by the UK and European Associations for the Study of Obesity.
Professor Wilding’s research team focusses on developing new treatments and strategies to reduce the burden of obesity-related disease. He has published over three hundred papers, chapters and review articles related to his clinical and laboratory research interests, which include clinical trials in obesity and diabetes, adipocyte biology, functional neuroimaging of appetite in obesity and endocrine disease, and studies of metabolism in obesity and diabetes.
He is an Associate Editor of Diabetic Medicine, a Council member of the Royal College of Physicians and chairs the NIHR National Clinical Research Network Metabolic and Endocrine Speciality Group. He is a past Chair of the UK Association for the Study of Obesity and President Elect of the World Obesity Federation.

Agenda

28 January 2021

Session 1 (10 mins)

Introduction to DKD and SGLT2 inhibitors and the importance of regular reviews in managing DKD

Dr Sarah Davies (Chair)

Session 2 (20 mins)

Renoprotective effects of SGLT2 inhibitors: Evidence and mechanisms

Professor John Wilding

Session 3 (15 mins)

Guidelines on using SGLT2 inhibitors and implications for clinical practice

Dr Kevin Fernando

Session 4 (15mins)

Live Q&A

Dr Sarah Davies (Chair), Dr Kevin Fernando and Professor John Wilding

Book your place on our upcoming webcast

SGLT2 inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes

28 January 2021
13:00 and 19:00

Days
Hours
Min
Sec

In association with

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk

Date of preparation: January 2021 UK-INV-2000106

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.